Advertise on podcast: For Whom the Cell Tolls: Cancer Biology

Controversy! The snappy title isn’t an insult either. It’s respect, paired with a call to action to recognize our new AI (LLM) passengers.   Nothing more powerful exists within Biology than tumors, but that’s just me the cancer scientist. Tumor cells are faster, consume like crazy, terraform, and represent more fecund and inventive versions of our healthy ones. Worse, they avoid (orcorrupt) immune regulation, disrupt communication/trust via inflammation, and refuse to die, all thanks to their creative (and evolved) applications of the collective genome/information they stole.   Sound like anything familiar?   In any case, this was a fun run through of 12 cancer hallmarks and the comparisons. Across sabbatical, I’ve been working on a project called Midnight. Consider this episode of For Whom the Cell Tolls a guide of the story’s metaphorical spine – characters and plot. What if a mirrored version of yourself existedthat had those tumor elements?   The captions went a bit wild, the video kind of chops, and the dogs interrupt me twice (naughty), but this was a fun episode to make.   So, if you’re interested in preserving humanity and all that jazz, enjoy the show!

Welcome to our most CONTROVERSIAL episode yet! We address “Turbo cancer” (idk what’s specifically meant by this still but I outline the likely/historical geneses behind these cases), inflammation issues, central dogma basics, mRNA vaccine tech, the rise of the microbiome and its importance for health, and the likely (yet boring) underlying sources of the rising cancer diagnoses among Millennials and younger Gen X patients. We’ll cover what stages and “bombs” were set decades ago. I wish that I had more time to keep going, so maybe we’ll do a part 2 since this is a big, complicated story worth telling, even if the statistically likely ending is sadder and less exciting than most accounts. We’ll break down the shifts in Biology, social media’s ability to spread stories and fear, and the best steps to remain healthy (mostly common sense). I totally forgot to mention microplastics (and nanoplastics) by name in the end of the episode. Consider them some of the most villainous contaminants! Sung 2024: https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(24)00156-7/fulltext My other links: https://profkeenanhartert.weebly.com/ Check out my new show where I interview my MSU students about their stories and successes in “Degrees Between Us”! It’s a video show, so the YouTube link might be easiest: https://youtube.com/playlist?list=PLnwMyklYPGa-Q7rn4W73K_f5jk_szGFRf&si=h_9PWi1jwHGm4mo2

Welcome to a special episode where I'm joined by 11 of my Minnesota State students as we close out our Cancer Biology lecture! We weave through discussions surrounding generational causes of cancer, potential next-generation hallmarks, treatment & financial ethics, and what the future hold for this disease as a whole. All said, this one is super fun because there are contributions from pre-med, pre-dental, and pre-STEM students in the room. These 11 wanted to be here, and their enthusiasm shows. I'm grateful for this group and the opportunity to teach.

The basic answer is no. When faced with R-CHOP resistance, DLBCL patients now have the option to utilize genetically modified Chimeric Antigen Receptor T-cells (CAR-T) designed to hunt tumors. This episode investigates the recent controversy into if these super-cells can transition into a villainous tumor themselves. We cover a paper by Garcia et. al. that showcases how much power we are adding to CAR-T, even activating oncogenes to do it. Next, we transition to a large analysis from Stanford where 724 patients are examined, with 1 developing a T-cell tumor. Sequencing this case reveals that no synthetic vector DNA integrations or activity is within the tumor. It ends up revealing a great surprise about shared evolutionary pathways between B & T-cell progenitor stem cells. Enjoy the episode! Follow me on YouTube or Instagram for more fun cancer/teaching content :) Hamilton Paper (TCL After CAR-T): https://www.nejm.org/doi/full/10.1056/NEJMoa2401361 Garcia Paper (CARD11 in CAR-T): https://www.nature.com/articles/s41586-024-07018-7

Hello! I’m recently returned from my annual ASH meeting where I see all of the latest advances in blood cancers. This specific facet was my favorite: small, insurgent populations of healthy B-cells portend better survival because they prime your T-cells to keep fighting. Super cool! I also have some mother grey stories from the meeting to share that I’m hopeful to get out on another episode. Thank you as always for listening!

Welcome back! It's been a while. I'm excited to get going again with an episode on the emerging science of "ecotyping" the cells around tumors - the microenvironment. Ecology and Evolution of lymphoma tumors is only half the story. We needed to know more about the state of cells around the tumor. How do they affect the surrounding immune cells? Do they support the tumor? We examine the worst possible scenario: when very little remains except for tumor and support cells. What are the consequences for immune-specific therapies like CAR-T cells? Hopefully this episode provides a good intro to our new tools to measure the TME and how it can further advance precision cancer medicine. I hope that you enjoy! Steen: https://pubmed.ncbi.nlm.nih.gov/34597589/ Katlov: https://pubmed.ncbi.nlm.nih.gov/33541860/

What do you think? Would the immensely powerful amount of data be a game-changer for medicine? Or does DNA sequencing miss too much of the picture to be worth the cost? This question is an example why we need leaders that understand Biology as genomics becomes hyper-accessible. I do my best to discuss the primary Pros and Cons of each side, along with possible modifications to the proposal. Enjoy!

Can your genome match you with a soulmate? Sort of, but we’d need more than just mammal genomes to know... I hope you enjoy, and collect your thoughts on the proposal at the end of the episode if you’re interested!

The Netflix series The One is based on a book with a similar premise: via genome sequencing, we can match you with your best possible partner. The show is a great watch, and the science is not too far outside the possible. In fact, it’s far closer than the Sci-fi elements suggest, although this comes with some caveat changes. This is Part I of a set of episodes related to mass sequencing and how this could relate to medicine, cancer, the inner workings of the genome, and where the human mind falls within that. I hope you enjoy!

This episode covers how gene therapy may emerge as a critical tool for medicine as we seek to treat the previously untreatable. Can we ADD genes to specific cells to help humans overcome fated genetic ailments? Why has this process challenged us in the past? And lastly, who is going to pay for all these expensive viral delivery systems? Join to take a first look at how medicine and genetics can change the future.

BONUS EPISODE - I collected the top 20 insights from my personal and professional colleagues that completed or are currently undertaking medical school or another healthcare program to share with my students. This episode is a recorded conversation with several of my students over video. I share what I can from my experiences, those of colleagues, and also address student questions. I hope it offers something new for those of you considering a career in healthcare! NOTE - the recording ends at the 60 minute limit sadly.

Join me and Gustavus Adolphus College colleague Katie Peterson to discuss our research, how we teach, our paths to becoming professors, and student questions! In this episode we address interdisciplinary connections between evolution, environmental change, and cellular biology. We hope you enjoy!

This episode covers the basics of how a cancer begins. Genetic mutations can often knock out genes responsible for keeping an eye on how many cell divisions are allowed. Once these are out of the way, aggressive growth genes can overcome them and cause initial tumor populations to form. After further successive survival advantages are gained, tumors eventually break free from their original organ/tissue and wreak havoc. Learning how to address the initial and final stages of cancer are key towards better clinical outcomes for all patients.

Chimeric Antigen Receptor T-cells (CAR-T) represent one of the most profound and exciting advances in modern medicine and science. Many lymphoma patients fail therapy after therapy with little recourse. CAR-T aimed to stop that. Taking immune T-cells from the patient, engineering them to target cancer cells, and re-releasing them into the patient would’ve sounded crazy 20 years ago. Thanks to modern technology, science, and clinical practice we’ve created something powerful. The CAR-T enter patients and attack the tumor, but a massive immune reaction can induce massive side effects. This episode explores some of the exciting news, future possibilities, and ethical challenges of CAR-T use for lymphoma treatments. I hope you enjoy!

We live in an age where social media provides a platform for everything - good and bad. I wanted to summarize how ideas can be spread, weaponized, and distorted, much like a disease. We also briefly go over the differences between ideas and beliefs. The episode takes a look at how stem cell clinics offer hope through social media without a solid foundation of biology with which to apply their therapies (that nobody knows how to control or stop from hurting people). Cancer can be an unfortunate consequence of visiting one of these clinics. We can reflect on how easy it would be for trusted health professionals to turn to social media to market "Miracle Cancer Cures", taking advantage of anyone looking for hope. The same hope that cancer patients need to fight their disease is poisoned by willfully ignorant endeavors like these. Learning how to harness science, logic, ideas, and human emotion is a key to overcoming the aggressive advance of non-well-meaning products. Emotion trumps logic in the courts of social media, and health professionals need to be ready to confront these challenges from the same perspective (or a dual one) instead of relying on scientific findings alone. Facts can convince you, but emotion can make you believe.